"Depression is a common risk for people who have lost their vision from age-related macular degeneration (AMD), but a new study shows that a type of rehabilitation therapy can cut this risk in half. The study was funded by the National Eye Institu"...
The following adverse reactions are described below and elsewhere in the labeling:
- Decreased Vision [see WARNINGS AND PRECAUTIONS]
- Intravitreal Injection Procedure Associated Effects [see WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION]
- Potential for Lens Subluxation [see WARNINGS AND PRECAUTIONS]
- Retinal Breaks [see WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates in one clinical trial of a drug cannot be directly compared with rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice.
Approximately 800 patients have been treated with an intravitreal injection of JETREA. Of these, 465 patients received an intravitreal injection of ocriplasmin 0.125 mg (187 patients received vehicle) in the 2 vehicle-controlled studies (Study 1 and Study 2).
The most common adverse reactions (incidence 5% -20% listed in descending order of frequency) in the vehicle-controlled clinical studies were: vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema.
Less common adverse reactions observed in the studies at a frequency of 2% - < 5% in patients treated with JETREA included macular edema, increased intraocular pressure, anterior chamber cell, photophobia, vitreous detachment, ocular discomfort, iritis, cataract, dry eye, metamorphopsia, conjunctival hyperemia, and retinal degeneration.
Dyschromatopsia was reported in 2% of patients injected with JETREA, with the majority of cases reported from two uncontrolled clinical studies. In approximately half of these dyschromatopsia cases there were also electroretinographic (ERG) changes reported (a-and b-wave amplitude decrease).
As with all therapeutic proteins, there is potential for immunogenicity. Immunogenicity for this product has not been evaluated.
Read the Jetrea (ocriplasmin injection) Side Effects Center for a complete guide to possible side effects
No information provided.
Last reviewed on RxList: 6/27/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Jetrea Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.